CO2017009217A2 - Métodos de preparación de polinucleótidos de tiofosforamidato n3’→p5’ usando composiciones salinas de cationes multivalentes - Google Patents

Métodos de preparación de polinucleótidos de tiofosforamidato n3’→p5’ usando composiciones salinas de cationes multivalentes

Info

Publication number
CO2017009217A2
CO2017009217A2 CONC2017/0009217A CO2017009217A CO2017009217A2 CO 2017009217 A2 CO2017009217 A2 CO 2017009217A2 CO 2017009217 A CO2017009217 A CO 2017009217A CO 2017009217 A2 CO2017009217 A2 CO 2017009217A2
Authority
CO
Colombia
Prior art keywords
polynucleotide
salt
multivalent cation
thiophosphoramidate
methods
Prior art date
Application number
CONC2017/0009217A
Other languages
English (en)
Spanish (es)
Inventor
Premchandran H Ramiya
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corp filed Critical Geron Corp
Publication of CO2017009217A2 publication Critical patent/CO2017009217A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C12N15/101Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/26Preparation of nitrogen-containing carbohydrates
    • C12P19/28N-glycosides
    • C12P19/30Nucleotides
    • C12P19/34Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • C12N2310/113Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/314Phosphoramidates
    • C12N2310/3145Phosphoramidates with the nitrogen in 3' or 5'-position
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • C12N2310/3515Lipophilic moiety, e.g. cholesterol
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y207/00Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07Nucleotidyltransferases (2.7.7)
    • C12Y207/07049RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CONC2017/0009217A 2015-04-23 2017-09-12 Métodos de preparación de polinucleótidos de tiofosforamidato n3’→p5’ usando composiciones salinas de cationes multivalentes CO2017009217A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562151891P 2015-04-23 2015-04-23
PCT/US2016/028657 WO2016172346A1 (en) 2015-04-23 2016-04-21 Methods of polynucleotide preparation using multivalent cation salt compositions

Publications (1)

Publication Number Publication Date
CO2017009217A2 true CO2017009217A2 (es) 2018-02-20

Family

ID=55911083

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0009217A CO2017009217A2 (es) 2015-04-23 2017-09-12 Métodos de preparación de polinucleótidos de tiofosforamidato n3’→p5’ usando composiciones salinas de cationes multivalentes

Country Status (36)

Country Link
US (2) US10745687B2 (https=)
EP (1) EP3286203B1 (https=)
JP (4) JP2018513127A (https=)
KR (1) KR102401252B1 (https=)
CN (2) CN107429247B (https=)
AU (2) AU2016250576C1 (https=)
BR (1) BR112017019627B1 (https=)
CA (1) CA2978191C (https=)
CL (1) CL2017002314A1 (https=)
CO (1) CO2017009217A2 (https=)
CY (1) CY1123197T1 (https=)
DK (1) DK3286203T3 (https=)
EA (1) EA035885B1 (https=)
ES (1) ES2798270T3 (https=)
HR (1) HRP20201218T1 (https=)
HU (1) HUE051148T2 (https=)
IL (1) IL254222A0 (https=)
LT (1) LT3286203T (https=)
MA (2) MA42157A (https=)
MD (1) MD3286203T2 (https=)
ME (1) ME03811B (https=)
MX (1) MX383293B (https=)
MY (1) MY187804A (https=)
PE (2) PE20221275A1 (https=)
PH (1) PH12017501927B1 (https=)
PT (1) PT3286203T (https=)
RS (1) RS60645B1 (https=)
SA (1) SA517390103B1 (https=)
SG (2) SG11201707893RA (https=)
SI (1) SI3286203T1 (https=)
SM (1) SMT202000389T1 (https=)
TN (1) TN2017000411A1 (https=)
TW (1) TWI736532B (https=)
UA (1) UA124521C2 (https=)
WO (1) WO2016172346A1 (https=)
ZA (1) ZA201706041B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA42157A (fr) 2015-04-23 2018-02-28 Geron Corp Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalent
AU2016341309A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Cancer vaccines
US11384352B2 (en) 2016-12-13 2022-07-12 Modernatx, Inc. RNA affinity purification
EP3554556B1 (en) 2016-12-19 2022-03-09 Ventana Medical Systems, Inc. Peptide nucleic acid conjugates
MA49914A (fr) * 2017-08-18 2021-04-21 Modernatx Inc Procédés analytiques par hplc
JP7441455B2 (ja) * 2017-09-22 2024-03-01 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイト 筋ジストロフィーの処置のためのチオモルホリノオリゴヌクレオチド
JP7727385B2 (ja) * 2017-12-18 2025-08-21 ヴェンタナ メディカル システムズ, インク. ペプチド核酸コンジュゲート

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046720A (en) 1974-01-17 1977-09-06 California Institute Of Technology Crosslinked, porous, polyacrylate beads
US4413070A (en) 1981-03-30 1983-11-01 California Institute Of Technology Polyacrolein microspheres
US4678814A (en) 1981-03-30 1987-07-07 California Institute Of Technology Polyacrolein microspheres
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US4659774A (en) 1985-11-01 1987-04-21 American Hoechst Corporation Support for solid-phase oligonucleotide synthesis
DE69120821T2 (de) 1990-08-31 1997-01-23 The Regents Of The University Of Minnesota, Minneapolis, Minn. Polyethylenglykol-Derivate für Festphasenanwendungen
US5281701A (en) 1991-07-12 1994-01-25 Applied Biosystems, Inc. Process and compounds for RNA synthesis
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
US5726297A (en) 1994-03-18 1998-03-10 Lynx Therapeutics, Inc. Oligodeoxyribonucleotide N3' P5' phosphoramidates
US5599922A (en) 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
CZ274596A3 (en) 1994-03-18 1997-03-12 Lynx Therapeutics Oligonucleotide n3 - p5 phosphoramidates and process of their synthesis and hybridization
US5684143A (en) 1996-02-21 1997-11-04 Lynx Therapeutics, Inc. Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
US5859233A (en) 1996-02-21 1999-01-12 Lynx Therapeutics, Inc. Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates
CA2274586A1 (en) 1996-12-20 1998-07-02 Geron Corporation Methods for detecting and inhibiting the rna component of telomerase
US5998604A (en) 1997-09-15 1999-12-07 The Perkin-Elmer Corporation Polynucleotide purification method
US6114519A (en) 1997-10-15 2000-09-05 Isis Pharmaceuticals, Inc. Synthesis of sulfurized oligonucleotides
US6465628B1 (en) 1999-02-04 2002-10-15 Isis Pharmaceuticals, Inc. Process for the synthesis of oligomeric compounds
CN1317291C (zh) 1999-09-10 2007-05-23 杰龙公司 寡核苷酸n3′→p5′硫代氨基磷酸酯,其合成及应用
JP2002060341A (ja) 2000-08-21 2002-02-26 Terumo Corp 止血剤
US7563618B2 (en) 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
CA2440322C (en) 2001-03-23 2014-09-09 Geron Corporation Oligonucleotide conjugates
PL1667522T3 (pl) * 2003-09-09 2018-06-29 Geron Corporation Zmodyfikowane oligonukleotydy do hamowania telomerazy
US20120329858A1 (en) 2010-08-04 2012-12-27 Geron Corporation Modified oligonucleotides for telomerase inhibition
TW200540180A (en) 2004-05-28 2005-12-16 Sankyo Co Telomerase inhibitor ena oligonucleotide
HRP20171705T1 (hr) 2004-07-02 2017-12-15 Geron Corporation Sinteza zaštićenih 3’-amino-nukleozidnih monomera
US20070212704A1 (en) * 2005-10-03 2007-09-13 Applera Corporation Compositions, methods, and kits for amplifying nucleic acids
JP5732196B2 (ja) * 2006-11-01 2015-06-10 バイオジェン アイデック エムエー インコーポレイティドBiogen Idec Inc. 低pHおよび二価カチオンを用いる生物高分子を単離する方法
BR112013003875B1 (pt) 2010-08-20 2021-10-05 Replicor Inc Composições farmacêuticas compreendendo complexo de quelato de oligonucleotídeo, formulação de oligonucleotídeo, e usos
US9106103B2 (en) 2011-09-23 2015-08-11 Eaton Corporation Unintteruptible power supply systems and methods employing on-demand energy storage
US9006630B2 (en) 2012-01-13 2015-04-14 Altasens, Inc. Quality of optically black reference pixels in CMOS iSoCs
AR091065A1 (es) 2012-05-18 2014-12-30 Replicor Inc Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral
JP6450308B2 (ja) * 2012-06-14 2019-01-09 ライフ テクノロジーズ コーポレーション ポリメラーゼ連鎖反応(pcr)のための新規の組成物、方法、およびキット
RS59363B1 (sr) * 2012-12-07 2019-11-29 Geron Corp Upotreba inhibitora telomeraze imetelstata za lečenje mijelofibroze
JOP20200257A1 (ar) * 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها
MA42157A (fr) 2015-04-23 2018-02-28 Geron Corp Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalent

Also Published As

Publication number Publication date
AU2016250576B2 (en) 2021-02-04
SI3286203T1 (sl) 2020-10-30
BR112017019627B1 (pt) 2022-11-29
CN107429247A (zh) 2017-12-01
CA2978191A1 (en) 2016-10-27
BR112017019627A2 (pt) 2018-05-15
JP2021152079A (ja) 2021-09-30
EP3286203B1 (en) 2020-05-06
WO2016172346A1 (en) 2016-10-27
EP3286203A1 (en) 2018-02-28
PH12017501927A1 (en) 2018-03-05
CN107429247B (zh) 2021-08-13
AU2016250576C1 (en) 2021-05-06
US20200339975A1 (en) 2020-10-29
MD3286203T2 (ro) 2020-08-31
ZA201706041B (en) 2020-11-25
LT3286203T (lt) 2020-07-27
PE20171785A1 (es) 2017-12-27
JP2018513127A (ja) 2018-05-24
SMT202000389T1 (it) 2020-09-10
DK3286203T3 (da) 2020-06-02
CY1123197T1 (el) 2021-10-29
US20160312227A1 (en) 2016-10-27
MA42157A (fr) 2018-02-28
PH12017501927B1 (en) 2022-09-02
TW201706284A (zh) 2017-02-16
US11441144B2 (en) 2022-09-13
JP2025061848A (ja) 2025-04-11
CL2017002314A1 (es) 2018-05-04
PT3286203T (pt) 2020-07-08
MX383293B (es) 2025-03-13
CN113564168B (zh) 2024-10-25
ME03811B (me) 2021-04-20
HUE051148T2 (hu) 2021-03-01
KR102401252B1 (ko) 2022-05-24
SA517390103B1 (ar) 2021-07-14
KR20170138399A (ko) 2017-12-15
CA2978191C (en) 2022-10-04
JP2022168017A (ja) 2022-11-04
TWI736532B (zh) 2021-08-21
CN113564168A (zh) 2021-10-29
NZ735042A (en) 2021-11-26
PE20221275A1 (es) 2022-09-01
AU2021202803A1 (en) 2021-06-03
TN2017000411A1 (en) 2019-01-16
HRP20201218T1 (hr) 2020-12-11
US10745687B2 (en) 2020-08-18
ES2798270T3 (es) 2020-12-10
SG11201707893RA (en) 2017-11-29
AU2016250576A1 (en) 2017-09-21
MY187804A (en) 2021-10-26
IL254222A0 (en) 2017-10-31
EA035885B1 (ru) 2020-08-27
EA201791753A1 (ru) 2018-04-30
SG10201909816PA (en) 2019-11-28
UA124521C2 (uk) 2021-10-05
RS60645B1 (sr) 2020-09-30
HK1251234A1 (en) 2019-01-25
MX2017011642A (es) 2017-11-02
MA42569B1 (fr) 2020-08-31

Similar Documents

Publication Publication Date Title
CO2017009217A2 (es) Métodos de preparación de polinucleótidos de tiofosforamidato n3’→p5’ usando composiciones salinas de cationes multivalentes
CO2017011957A2 (es) Variantes de alfa-amilasa y polinucleótidos que codifican las mismas
CL2016002010A1 (es) Métodos y sistemas para generar mapas colaborativos compartidos
MX2017011329A (es) Productos terapeuticos de anticuerpos que se enlazan a cd47.
CO2018002196A2 (es) Proteínas de fusión de factor ix y métodos para producirlas y utilizarlas
CL2018001770A1 (es) Composiciones de decil mercaptanos mezclados y uso de las mismas como colectoras de productos químicos de minería
BR112014009066B8 (pt) molécula de ácido nucleico, método para a sintetização de uma molécula de dna de triciclo-fosforotioato e composição farmacêutica
BR112017007411A2 (pt) método em a máquina de plantio de mudas e máquina de plantio de mudas
MX2019007248A (es) Enzimas de polimerizacion para reacciones de secuenciacion.
BR112017015414A2 (pt) máquina fresadora e método de aplicação da máquina fresadora
BR112017000135B8 (pt) Processo para a preparação de ácidos 4-alcóxi-3-hidroxipicolínico
BR112016025196A2 (pt) composições de oligonucleotídeo e métodos de fazê-las
MX2017008410A (es) Reduccion selectiva de residuos cisteina en anticuerpos il-17.
BR112014020929A2 (pt) alinhamento de imagem de imagens de mama
BR112014015288A2 (pt) máquina e processo para tornear pelo menos ressaltos planos de um eixo de manivela que circunda pinos de manivela
MX2017000023A (es) Proceso para preparar fenilalcanos sustituidos.
MX2021015698A (es) Integración dirigida de configuraciones aleatorias de ácidos nucleicos.
CR20130662A (es) Anticuerpos a adp-ribosil ciclasa 2
MX375894B (es) Uso de acido alcanosulfonico para limpieza en las industrias azucareras.
BR112017026203A2 (pt) método de geração de uma estratégia de produção para a explotação de um reservatório de hidrocarbonetos em um ambiente natural
DOP2015000294A (es) Preparado farmacéutico
BR112016024466A2 (pt) método para a síntese de clofarabina
BR112015030065A2 (pt) sistema de deslocamento de fase
BR112018074079A2 (pt) unidade de produção de sumo que tem um apoio
MX367808B (es) Método de búsqueda y aparato de búsqueda.